Joint Formulary & PAD

Desmopressin acetate - Nocturnal polyuria

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral lyophilisates
Associated Icons :
SPC
Restrictions / Comments :
Important

Initiation and 1 month supply by the specialist before any request for primary care prescribing.

Women - 25mcg dose

Men - 50mcg dose

PAD Profile

ChemicalSubstance :
Desmopressin acetate
Indication :
Nocturnal polyuria
Group Name :
Keywords :
vasopressin analogue, LUTS, nocturia
Brand Names Include :
Noqdirna
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey and North West Sussex Area Prescribing Committee (APC) recommends desmopressin (Noqdirna) as a treatment option for idiopathic noturnal polyuria.

Desmopressin (Noqdirna) is a licensed product and should be prescibed as an alternative to other, off label desmopressin preparations.

Desmopressin (Noqdirna) will be assigned a BLUE (no information sheet) traffic light status and specialists in secondary care will be required to prescribe at least 1 month of desmopressin prior to requesting transfer of care with the patients primary care provider.

The attached nocturia treatment pathway has been developed in conjunction with colleagues at Ashford & St Peters Hospitals NHS Foundation Trust and is expected to compliment the information all ready available for prescribers on this page. See below for further information 

Other Indications

Below are listed other indications that Desmopressin acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Nocturnal polyuria.

  • No records returned.